Illumina (NASDAQ:ILMN) Updates FY 2022 Earnings Guidance

Illumina (NASDAQ:ILMNGet Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share guidance of $4.00-$4.20 for the period, compared to the consensus earnings per share estimate of $4.15. The company issued revenue guidance of $5.16 billion-$5.25 billion, compared to the consensus revenue estimate of $5.23 billion.

A number of equities analysts recently weighed in on the stock. Robert W. Baird dropped their target price on shares of Illumina from $437.00 to $380.00 in a research report on Friday, February 11th. StockNews.com initiated coverage on Illumina in a research note on Thursday, March 31st. They set a hold rating on the stock. SVB Leerink decreased their price objective on Illumina from $430.00 to $400.00 and set a market perform rating on the stock in a research report on Friday, February 11th. Piper Sandler lifted their target price on Illumina from $450.00 to $460.00 and gave the stock an overweight rating in a report on Tuesday, February 15th. Finally, Cowen reduced their target price on shares of Illumina from $506.00 to $492.00 in a research note on Friday. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $440.77.

ILMN traded down $26.94 on Monday, hitting $222.11. The company had a trading volume of 49,727 shares, compared to its average volume of 957,913. The stock has a fifty day moving average price of $330.74 and a 200-day moving average price of $357.46. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.09 and a current ratio of 2.48. Illumina has a 12-month low of $239.03 and a 12-month high of $526.00. The stock has a market capitalization of $34.89 billion, a price-to-earnings ratio of 54.14, a P/E/G ratio of 1.93 and a beta of 0.99.

Illumina (NASDAQ:ILMNGet Rating) last announced its earnings results on Thursday, May 5th. The life sciences company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.20. Illumina had a return on equity of 8.86% and a net margin of 15.04%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same period in the previous year, the business earned $1.89 EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. Analysts forecast that Illumina will post 4.14 EPS for the current fiscal year.

In related news, SVP Phillip G. Febbo sold 1,988 shares of the company’s stock in a transaction that occurred on Wednesday, April 6th. The stock was sold at an average price of $360.01, for a total value of $715,699.88. Following the sale, the senior vice president now owns 5,774 shares in the company, valued at $2,078,697.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Charles Dadswell sold 368 shares of Illumina stock in a transaction that occurred on Monday, March 28th. The shares were sold at an average price of $342.83, for a total transaction of $126,161.44. The disclosure for this sale can be found here. Insiders sold a total of 5,198 shares of company stock valued at $1,819,471 over the last ninety days. 0.13% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ILMN. Forum Financial Management LP acquired a new stake in Illumina during the fourth quarter valued at $285,000. Comerica Bank grew its position in shares of Illumina by 1.4% during the 4th quarter. Comerica Bank now owns 19,860 shares of the life sciences company’s stock valued at $6,846,000 after acquiring an additional 267 shares during the period. Kingsview Wealth Management LLC grew its position in shares of Illumina by 14.4% during the 4th quarter. Kingsview Wealth Management LLC now owns 859 shares of the life sciences company’s stock valued at $327,000 after acquiring an additional 108 shares during the period. Toroso Investments LLC increased its stake in shares of Illumina by 40.0% in the 4th quarter. Toroso Investments LLC now owns 3,176 shares of the life sciences company’s stock valued at $1,208,000 after purchasing an additional 908 shares in the last quarter. Finally, Horizon Investments LLC raised its holdings in Illumina by 8.4% in the 4th quarter. Horizon Investments LLC now owns 1,060 shares of the life sciences company’s stock worth $403,000 after purchasing an additional 82 shares during the period. 86.62% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Stories

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.